Asad Haider
Stock Analyst at Goldman Sachs
(4.68)
# 799
Out of 5,014 analysts
130
Total ratings
85.7%
Success rate
25%
Average return
Main Sectors:
Stocks Rated by Asad Haider
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BNTX BioNTech SE | Maintained: Buy | $127 | $98.86 | +28.46% | 7 | Sep 15, 2026 | |
| JNJ Johnson & Johnson | Reiterated: Buy | $282 | $266.32 | +5.89% | 24 | Aug 25, 2026 | |
| MRK Merck & Co. | Reiterated: Buy | $140 → $160 | $144.85 | +10.46% | 21 | Aug 20, 2026 | |
| LLY Eli Lilly and Company | Reiterated: Buy | $1,283 → $1,367 | $1,138.28 | +20.09% | 24 | Aug 6, 2026 | |
| RPRX Royalty Pharma | Reiterated: Buy | $59 → $66 | $59.05 | +11.77% | 4 | Aug 6, 2026 | |
| PFE Pfizer | Reiterated: Hold | $26 | $27.72 | -6.20% | 20 | Aug 4, 2026 | |
| ABBV AbbVie | Reiterated: Hold | $244 | $261.77 | -6.79% | 8 | Jul 21, 2026 | |
| BMY Bristol-Myers Squibb Company | Reiterated: Hold | $61 | $64.10 | -4.84% | 11 | Jul 20, 2026 | |
| NAMS NewAmsterdam Pharma Company | Reiterated: Hold | $37 → $38 | $22.36 | +69.95% | 4 | May 7, 2026 | |
| INVA Innoviva | Reiterated: Sell | $17 → $18 | $20.90 | -13.88% | 2 | May 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $38 → $67 | $59.54 | +12.53% | 2 | Feb 26, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | $270 | $381.50 | n/a | 1 | Dec 16, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | $66 | $10.38 | n/a | 1 | Dec 16, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $168 | $168.94 | n/a | 1 | Dec 14, 2018 |
BioNTech SE
Sep 15, 2026
Maintained: Buy
Price Target: $127
Current: $98.86
Upside: +28.46%
Johnson & Johnson
Aug 25, 2026
Reiterated: Buy
Price Target: $282
Current: $266.32
Upside: +5.89%
Merck & Co.
Aug 20, 2026
Reiterated: Buy
Price Target: $140 → $160
Current: $144.85
Upside: +10.46%
Eli Lilly and Company
Aug 6, 2026
Reiterated: Buy
Price Target: $1,283 → $1,367
Current: $1,138.28
Upside: +20.09%
Royalty Pharma
Aug 6, 2026
Reiterated: Buy
Price Target: $59 → $66
Current: $59.05
Upside: +11.77%
Pfizer
Aug 4, 2026
Reiterated: Hold
Price Target: $26
Current: $27.72
Upside: -6.20%
AbbVie
Jul 21, 2026
Reiterated: Hold
Price Target: $244
Current: $261.77
Upside: -6.79%
Bristol-Myers Squibb Company
Jul 20, 2026
Reiterated: Hold
Price Target: $61
Current: $64.10
Upside: -4.84%
NewAmsterdam Pharma Company
May 7, 2026
Reiterated: Hold
Price Target: $37 → $38
Current: $22.36
Upside: +69.95%
Innoviva
May 6, 2026
Reiterated: Sell
Price Target: $17 → $18
Current: $20.90
Upside: -13.88%
Feb 26, 2026
Reiterated: Hold
Price Target: $38 → $67
Current: $59.54
Upside: +12.53%
Dec 16, 2019
Upgraded: Buy
Price Target: $270
Current: $381.50
Upside: n/a
Dec 16, 2019
Upgraded: Buy
Price Target: $66
Current: $10.38
Upside: n/a
Dec 14, 2018
Reiterated: Buy
Price Target: $168
Current: $168.94
Upside: n/a